Last reviewed · How we verify
NCT06272292: CAM-FAI adult
Biomechanical Investigation of Symptomatic FAI and Two Groups of Asymptomatic Controls
NA trial testing EOS in Femoroacetabular Impingement in 99 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Universitaire Ziekenhuizen KU Leuven |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 99 |
| Start date | 28 July 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- EOS
- 3D motion lab analysis
Conditions studied
- Femoroacetabular Impingement — all drugs for Femoroacetabular Impingement →
Sponsor
Universitaire Ziekenhuizen KU Leuven — full company profile →
Who can join
Adults 21 to 35, male only, with Femoroacetabular Impingement. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Femoroacetabular impingement (FAI) is an orthopaedic condition that is primarily characterized by the presence of anatomic bony abnormalities in the femoral head and/or the acetabulum resulting in an abnormal contact between the two during hip motion, especially in positions of increased hip flexion and rotation, ultimately leading to hip pain. Unfortunately, a FAI diagnosis is frequently only made once symptoms have become severe to an extent that they limit everyday life activities. Moreover, another important aspect that has been consistently overlooked in past FAI movement studies is the influence muscle strength and activation can have on movement pattern and symptom presentation. The diagnosis and management of FAI needs to be addressed through a more wholesome investigation of the biomechanical influence on the manifestation of symptoms. This project aims to further unravel the link between spinopelvic anatomy, its biomechanical contribution to femoro-pelvic motion and the manifestation of femoroacetabular impingement in adult male population. By, for the first time, integrating three-dimensional (3D) instrumented motion analysis with state-of-the-art full-body biplanar X-ray imaging (EOS imaging, Paris France), we will more specifically investigate the presence of an association between spinopelvic kinematics and the link to symptomatic FAI morphology, as well as investigate the presence of differences in these measures between symptomatic and asymptomatic subjects with comparable femoral morphology.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06272292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of EOS
Trials testing the same drug.
- NCT05921721 — Can EOS Hip Imaging Replace CT Hip Scans? · NA · unknown
- NCT05224908 — Breech Pelvimetry by EOS® Technique With Change of Maternal Position and Delivery Route · NA · completed
- NCT05122533 — Reliability of Clinical Limb-length Measurements Methods · completed
- NCT05108116 — Phenotyping the Alignment of the Lower Limb · completed
- NCT03863756 — Performance of EOS Imaging System in the Assessment of Spondyloarthritis Structural Changes Compared With Standard Radio · unknown
Other recruiting trials for Femoroacetabular Impingement
Currently open trials in the same condition.
- NCT06536088 — The Relationship Between Gait and Severity of Femoroacetabular Impingement · recruiting
- NCT05025956 — Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan · Phase 1, PHASE2 · active not recruiting
- NCT03891563 — Prospective Evaluation of Sport Activity and the Development of Femoroacetabular Impingement in the Adolescent Hip · active not recruiting
Other Universitaire Ziekenhuizen KU Leuven trials
Trials by the same sponsor.
- NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
- NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
- NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
- NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
- NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06272292 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
- Last refreshed: 16 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06272292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing